Skip to main content
Pulike Biological Engineering,Inc. logo

Pulike Biological Engineering,Inc. — Investor Relations & Filings

Ticker · 603566 ISIN · CNE1000025N0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,080 across all filing types
Latest filing 2024-03-13 Share Issue/Capital Cha…
Country CN China
Listing Shanghai Stock Exchange 603566

About Pulike Biological Engineering,Inc.

http://en.pulike.com.cn/

Pulike Biological Engineering, Inc. specializes in the research, development, and production of veterinary biological products and pharmaceutical preparations. The company focuses on animal disease prevention through the manufacture of high-end vaccines, diagnostic reagents, and veterinary medicines. Its product range primarily serves the swine and poultry sectors, featuring advanced biologicals such as genetically engineered vaccines and synthetic peptide products. Pulike maintains a strong emphasis on technological innovation, utilizing national-level research platforms to develop solutions for complex animal health challenges. The company’s core activities encompass the entire value chain from basic biotechnology research to the commercialization of veterinary health solutions, aiming to improve livestock productivity and biosecurity.

Recent filings

Filing Released Lang Actions
普莱柯关于2021年非公开发行限售股解禁上市流通的公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the lifting of restrictions on previously non-publicly issued shares, allowing them to be listed and traded. It details the number of shares becoming freely tradable, the lock-up periods, and changes in share capital structure. It also includes the verification opinion from the sponsoring institution. The document is not a financial report, earnings release, or management discussion but rather a formal disclosure about share circulation and stock listing changes. This fits the category of Share Issue/Capital Change announcements, as it concerns the change in status of shares and their circulation. The document length is 2733 characters, which is typical for an announcement rather than a full report. Therefore, the appropriate classification is SHA (Share Issue/Capital Change).
2024-03-13 Chinese
普莱柯关于拟投资设立私募股权投资基金的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by a company about its planned investment to establish a private equity investment fund. It details the investment amount, partners, fund structure, and associated risks. There are no financial statements or detailed financial performance data included. The document is a formal announcement of a capital investment activity, specifically about fund formation and investment commitments. It does not contain quarterly or annual financial results, audit opinions, or management discussions of financial results. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. The document length is about 4000 characters, which is consistent with an announcement rather than a full report. Hence, the classification is CAP with high confidence.
2024-03-12 Chinese
普莱柯关于股份回购进展情况的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from 普莱柯生物工程股份有限公司 regarding the progress of its share repurchase program. It details the board approval of the share buyback plan, the amount and price limits, and the actual repurchase progress including number of shares bought back, prices, and total amount spent. The document references regulatory rules on share repurchases and provides an update on the status as of February 2024. There is no financial statement or comprehensive financial report included, only an update on the share repurchase activity. This fits the definition of a Transaction in Own Shares (POS) filing, which reports on the company's buyback of its own shares.
2024-03-01 Chinese
普莱柯关于股份回购进展情况的公告
Transaction in Own Shares Classification · 95% confidence The document is a public announcement from 普莱柯生物工程股份有限公司 regarding the progress of its share repurchase program. It details the number of shares repurchased, prices, total amounts paid, and compliance with relevant regulations. The document does not contain financial statements or detailed financial analysis but focuses on the update of the company's share buyback activity. This matches the definition of a Transaction in Own Shares (POS) filing, which reports on the company's buyback or sale of its own shares. The document length is short (1070 characters), but it contains substantive information about the repurchase progress, not just a notice of report publication or certification. Therefore, the correct classification is POS with high confidence.
2024-01-31 Chinese
北京德恒律师事务所关于普莱柯生物工程股份有限公司2024年第一次临时股东大会的法律意见
Regulatory Filings Classification · 95% confidence The document is a legal opinion issued by a law firm regarding the legality of the convening, attendance, and voting procedures of a company's 2024 first extraordinary general meeting (临时股东大会). It details the meeting notice, attendance, voting methods, and results, and concludes on the legality and validity of the meeting and its resolutions. It does not contain financial statements or financial performance data, nor is it a report of voting results alone. It is a legal opinion on the shareholder meeting process and resolutions. This type of document is best classified as a Regulatory Filing (RNS) because it is a legal compliance document related to corporate governance and shareholder meetings but does not fit into more specific categories like Declaration of Voting Results (DVA) or Board/Management Information (MANG). The document length is under 5,000 characters, but it is not merely an announcement of a report publication; it is the legal opinion itself. Therefore, the appropriate classification is Regulatory Filings (RNS).
2024-01-23 Chinese
普莱柯2024年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at an extraordinary shareholders meeting (临时股东大会决议公告) held on January 23, 2024. It includes information about the meeting attendance, voting results on various proposals, and legal witness statements confirming the validity of the meeting and resolutions. The content focuses on the voting outcomes and procedural compliance rather than presenting financial data or management discussion. This matches the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA), which covers official results from shareholder votes at any general meeting. The document length is 2121 characters, which is sufficient for a detailed voting result announcement but too short and not suitable for a full report like an Annual or Interim Report. Therefore, the correct classification is DVA with high confidence.
2024-01-23 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.